Aligos Therapeutics Inc Revenue Growth Rates (ALGS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Aligos Therapeutics Inc   (NASDAQ: ALGS)
 

ALGS's Revenue Growth by Quarter and Year

Aligos Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ALGS/growth
https://api.csimarket.com/api/v1/companies/ALGS/fundamentals
https://api.csimarket.com/api/v1/companies/ALGS/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ALGS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 2.83
2nd Quarter June 27.78
1st Quarter March 2.83
FY 33.44

ALGSs Annual Revenue
Aligos Therapeutics Inc 's Revenue in the fiscal year 2025 $ 2.19 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2024 $ 3.95 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2023 $ 15.53 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2022 $ 13.91 millions
Aligos Therapeutics Inc 's Revenue in the fiscal year 2021 $ 4.36 millions




ALGS Revenue third quarter 2026 Y/Y Growth Comment
Aligos Therapeutics Inc achieved in the third quarter 2026, above Company average Revenue surge of 282.43% year on year, to $ 2.83 millions.

Looking into third quarter 2026 results within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Revenue growth. While Aligos Therapeutics Inc ' s Revenue doubling of 282.43% ranks overall at the positon no. 26 in the third quarter 2026.


ALGS Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 282.43 %
2nd Quarter June 2763.92 %
1st Quarter March 812.9 %
FY   -

Financial Statements
Aligos Therapeutics Inc 's third quarter 2026 Revenue $ 2.83 millions ALGS's Income Statement
Aligos Therapeutics Inc 's third quarter 2025 Revenue $ 0.74 millions Quarterly ALGS's Income Statement


ALGS Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -89.81 %
2nd Quarter June 881.63 %
1st Quarter March 1564.71 %
FY (Year on Year)   -


Back to ALGS Growth rate Comparisons >> Back to ALGS Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #11
Overall #26

Revenue Y/Y Growth Statistics
High Average Low
2778.55 % 250.56 % -84.59 %
(Jun 30 2026)   (Mar 31 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #11
Overall #26
Revenue Y/Y Growth Statistics
High Average Low
2778.55 % 250.56 % -84.59 %
(Jun 30 2026)   (Mar 31 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Aligos Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
1574.56 % 148.73 % -77.19 %
(Mar 31 2026)  


ALGS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aligos Therapeutics Inc disclosed fall in Revenue from the second quarter by -89.81% to $ 2.83 millions, from $ 27.78 millions achived in the previous reporting period.

But that's not important problem, as Aligos Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Aligos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 33.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #12
Overall #33
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #3
Healthcare Sector #12
Overall #33
Revenue Q/Q Growth Statistics
High Average Low
1574.56 % 148.73 % -77.19 %
(Mar 31 2026)  


ALGS's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Aligos Therapeutics Inc disclosed fall in Revenue from the second quarter by -89.81% to $ 2.83 millions, from $ 27.78 millions achived in the previous reporting period.

But that's not important problem, as Aligos Therapeutics Inc 's Revenue generally seem to plunge in this quarter.

Within Biotechnology & Pharmaceuticals industry 2 other companies have achieved higher Revenue quarter on quarter growth. While Aligos Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 33.


Aligos Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 31.52
Y / Y Revenue Growth (TTM) 893.01 %
Year on Year Revenue Growth Overall Ranking # 3646
Seqeuential Revenue Change (TTM) 569.88 %
Seq. Revenue Growth (TTM) Overall Ranking # 2864


Cumulative Revenue growth Comment
With 893.01% annual Revenue growth, Aligos Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 511 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2051 to 3646.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 512
Overall # 3646

Revenue TTM Y/Y Growth Statistics
High Average Low
893.01 %
 68.95 %
-76.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 406
S&P 500 # 2864
Cumulative Revenue growth Comment
With 893.01% annual Revenue growth, Aligos Therapeutics Inc would report a record annual Revenue surge if the fiscal year would end on Jun 30 2026.

In the Healthcare sector 511 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2051 to 3646.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 43
Healthcare Sector # 512
Overall # 3646

Revenue TTM Y/Y Growth Statistics
High Average Low
893.01 %
68.95 %
-76.29 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 43
Sector # 406
S&P 500 # 2864




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ALGS's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bio Green Med Solution Inc 460.49%$ 460.494 millions
Xencor Inc454.88%$ 454.884 millions
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions
Volitionrx Limited157.28%$ 157.283 millions


About Aligos Therapeutics Inc Revenue Growth Rates (ALGS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Aligos Therapeutics Inc (CIK 1799448).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-450798
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Aligos Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.